Evolve is a specialist pharmaceutical and biotechnology IP firm. Our team includes scientific experts in immunology, T cell biology, antibody engineering and biologics.
Related technologies: Antibodies | ADCs | CAR-T | In vivo CAR-T | Dosing regimens
T cell engagers are bispecific antibodies that bind a target on the diseased cell and a receptor on T cells, usually CD3, bringing the T cell close enough to kill its target. Amgen’s CD19 x CD3 engager blinatumomab led the way, and TCEs are now moving from blood cancers into solid tumours and autoimmune disease (Evolve Insights).
TCE innovation can lie in the target binder, the CD3 binder and its affinity, the format, including half-life extension and multispecific designs, conditional activation, the dosing regimen and step-up dosing, the management of cytokine release syndrome, combinations and new indications. A European patent on using a glucocorticoid alongside step-wise dosing of blinatumomab shows how valuable clinical IP can be for this class (Evolve Insights).
Popular targets such as BCMA, CD19, CD20 and Claudin 18.2 are pursued with antibodies, ADCs, CAR-T and TCEs at the same time (Evolve Insights). Patents on a binder usually cover it in any format, so freedom to operate and inventive step have to be assessed across modalities, not just against other TCEs.
The EPO applies its antibody case law to TCEs and other complex biologics, so a new TCE against a known target usually needs data showing an advantage over what is already known, such as better safety, a wider therapeutic window or improved efficacy (Evolve Insights). In the US, broad functional claims face strict written description and enablement requirements, and other major markets apply their own standards. Japan and China apply their own standards, and China is now an important source of new bispecifics and TCEs, so landscapes and filing strategy have to be global. Read more on our antibodies page.
Dosing schedules, step-up regimens, premedication, patient selection and new indications can all support valuable later filings. Because the dose usually forms part of the label, dose patents can provide protection long after the composition of matter patent expires (Evolve Insights). Read more on our dosing regimens page.
TCEs encoded by mRNA and delivered in lipid nanoparticles, or secreted by engineered cells, combine the TCE landscape with the delivery landscape. See our pages on LNPs and in vivo CAR-T.
Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP, managing the binder, format and delivery in-licences alongside your own filings, and keeping the strategy aligned with the clinical plan.
Why fractional IP counsel for TCE companies? T cell engagers sit where antibody, format and dosing IP meet, and the landscape moves quickly. A fractional head of IP from Evolve brings the real-world industry experience that you only get working in-house, keeps binder, format and delivery licences aligned with your own filings, and makes sure clinical inventions such as dosing are captured as the data emerges. Our team and AI tools give them support that a lone consultant lacks and a traditional IP firm rarely offers, with a global strategic approach.
Albert, our validity agent, maps the data and claims in competitor TCE and antibody patents, and its sequence module checks lead sequences against the claims. Gilbert, our quality agent, checks that our own claims really cover the lead before anything is filed. Our attorneys still make every judgement call. Read more about Evolve AI.
Often, yes. A claim to an antibody or binder as such usually covers it in any format, including a bispecific. Freedom to operate for a TCE therefore has to include antibody, ADC and CAR patents on the same target. Read more: Freedom to operate versus patentability
Yes, if it shows a technical advantage over what is already known, and the application includes the data to show it. In Europe, the EPO asks what problem the new TCE solves over the closest prior art.
Often, yes. Step-up dosing, premedication and dosing schedules can be inventive if they produce a surprising technical effect, such as reduced cytokine release syndrome, and they usually form part of the label. Read more: EPO pharma case law trends 2025: Clinical inventions
When the data support the claims you want. A study protocol on its own may not be enough to support a later dose or regimen claim, and your own conference abstracts and press releases can become prior art. Read more: A study protocol is not the same invention
We are happy to have an informal conversation about your programme, with no obligation. You can read more about our team, and we also write a regular newsletter on pharma and biotech IP.